- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT06321536
Respons på fremvoksende antimikrobiell resistens med inneslutningsmikrobiotaterapi (REACT)
Respons på fremvoksende antimikrobiell resistens med inneslutningsmikrobiotaterapi
REACT is a phase two, open-label, randomized, controlled trial of microbiota therapy (MT) to reduce colonization with multi-drug resistant organisms (MDRO). REACT is designed to assess the safety and efficacy of MT administered to subjects colonized with a MDRO. The overarching hypothesis is that MT can reduce MDRO colonization with safety that is comparable to observation.
Studieoversikt
Status
Intervensjon / Behandling
Detaljert beskrivelse
REACT is a phase two, open-label, randomized, controlled trial of microbiota therapy (MT) to reduce colonization with multi-drug resistant organisms (MDRO) in patients admitted to long-term care facilities. REACT is designed to test the safety and efficacy of instillation of donor intestinal microbiota.
Patients admitted to long-term care facilities (e.g. long-term acute care hospitals and ventilator-capable skilled nursing facilities) found to be MDRO colonized during prevalence screening activities performed in the related APPS study.
Facilities undergo prevalence sampling that involves participant peri-rectal, inguinal, and stool sampling to estimate the prevalence of targeted MDROs (CRE, ESBL, VRE, MDRP) under the accompanying APPS protocol. Patients who are positive with at least one targeted MDRO are eligible for an Emory manufactured MT product (via rectal enema or feeding tube), or observation followed by repeat sampling at Days 7, 14, 21, and 28. Participants will be followed with collection of data on adverse events/safety/changes in medications at Days 0, 7, 14, 21, 28, and followed up once a month for 6 months, after MT administration.
Studietype
Registrering (Faktiske)
Fase
- Fase 2
Kontakter og plasseringer
Studiesteder
-
-
Georgia
-
Atlanta, Georgia, Forente stater, 30329
- A.G Rhodes Wesley Woods
-
Decatur, Georgia, Forente stater, 30030
- Emory Long Term Acute Care (LTAC)
-
-
Illinois
-
Hinsdale, Illinois, Forente stater, 60521
- RML Specialty Hospital
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Forente stater, 19146
- Penn Medicine Rittenhouse
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Be able (or have available a Legal Authorized Representative who is able) to understand and sign a written informed consent document.
- Be at least 18 years old at the time of consent.
- Be able to comply with all study protocol requirements, including able to receive MT as retention enema or via enteral feeding tube and be available for the duration of the study follow up.
- Be colonized with a target MDRO (CRE, VRE, ESBL, MDR Pseudomonas) as detected by bacterial culture of stool or peri-rectal swab (collected in companion APPS facility prevalence sampling protocol).
- Be able to discontinue or complete planned courses of antibiotics, probiotics, and other microbiota restoration therapies by Day -1 and not resume until after Day 28.
- The effects of the MT on the developing human fetus are unknown. For this reason, persons of child-bearing potential (POCBP) and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation.
- Agree to refrain from receptive anal intercourse until the last biological specimen (stool sample or peri-rectal swab) is collected (Day 28).
Exclusion Criteria:
-
Are pregnant, breastfeeding, lactating, or planning a pregnancy during study duration (through 4 weeks after the last dose of investigational product, or MT), if POCBP.
-
Have known uncontrolled intercurrent illness(es):
- Symptomatic congestive heart failure
- Acute coronary syndrome
- Cardiac arrhythmia
- Untreated in-situ colorectal cancer
- Toxic megacolon
- Ileus
- Positive stool studies without completion of treatment course (including ova and parasites, Salmonella spp, Shigella, Campylobacter, and other enteropathogens).
- other acute illness that in the opinion of the investigator could affect the safety of the participant or make study data uninterpretable.
-
Are on systemic antibiotics for any reason other than treatment of recent MDRO infection or clear anticipated need for antibiotics during the follow up period that cannot be rescheduled (e.g. fluoroquinolone prophylaxis for percutaneous nephrostomy tube exchange, prolonged antibiotic course for endocarditis). Participants must complete the planned antibiotic course by study Day -1.
-
Have a compromised immune system, defined as:
- AIDS with CD4+ T-cell count <200 and detectable HIV viral load on most recent assay.
- Absolute neutrophil count (ANC) <1,000 neutrophils / mL on day of enrollment.
- Active malignancy requiring intensive induction chemotherapy, radiotherapy, or biologic treatment within 2 months prior to enrollment.
- History of hematopoietic cell transplantation, either allogeneic or autologous in the last 1 year.
-
Have a history of significant food allergy that led to anaphylaxis or hospitalization.
-
Have a life expectancy of 24 weeks or less
-
Have any condition that, in the opinion of the investigator, might interfere with study objectives or limit compliance with study requirements, including but not limited to:
- Known active intravenous drug or alcohol abuse
- Uncontrolled psychiatric illness
- Social situations (e.g. incarceration)
-
Received an interventional agent (drug, device, or procedure) within 28 days prior to enrollment.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Forebygging
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: Group 1: microbiota therapy (MT)
Group 1 will offer Microbiome therapeutic (MT) to all MDRO-positive patients (i.e., intervention condition). |
Participants will receive an Emory-manufactured MT product, delivered as 250mL via rectal enema or 30mL instillation via an existing functioning feeding tube with the rate adjusted to participant tolerance. Participants will receive three doses over the first seven days of the study.
Andre navn:
|
|
Ingen inngripen: Group 2: Observation
Group 2 will be assigned to observation. |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Difference in number of solicited Adverse Events (AEs)
Tidsramme: Day 0, Day 7 post-intervention
|
Difference in number of solicited AEs between Day 0 and Day 7 in AMG-treated vs Observation participants. |
Day 0, Day 7 post-intervention
|
|
Difference in severity of solicited AEs
Tidsramme: Day 0, Day 7 post-intervention
|
Difference in severity of solicited AEs will be compared in AMG-treated vs Observation participants. Graded as mild, moderate or severe, up to 7 days post-intervention. |
Day 0, Day 7 post-intervention
|
|
Difference in number of unsolicited AEs
Tidsramme: Day 0, Day 28 post-intervention
|
Difference in number of unsolicited AEs between Day 0 and Day 28 in AMG-treated vs Observation participants. |
Day 0, Day 28 post-intervention
|
|
Difference in severity of unsolicited AEs
Tidsramme: Day 0 and Day 28
|
Difference in severity of unsolicited AEs will be collected between Day 0 and Day 28. Graded as mild, moderate or severe and compared in AMG-treated vs Observation participants |
Day 0 and Day 28
|
|
Number of participants by composite MDRO Colonization and survival status
Tidsramme: Day 28 post-intervention
|
Participants will be classified into one of three ordinal categories: (1) alive without MDRO colonization, (2) alive with MDRO colonization, or (3) deceased. MDRO colonization is defined as a stool culture at Day 28 positive for any target multidrug-resistant organism (MDRO). |
Day 28 post-intervention
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Count of serious AEs (SAEs)
Tidsramme: Day 180 (6 months)
|
Count of serious AEs (SAEs) between Day 0 and Month 6 (Day 180) censored by last telephone visits or death, whichever is later. |
Day 180 (6 months)
|
|
Count of AEs of Special Interest (AESIs)
Tidsramme: Day 180 (6 months)
|
Count of AEs of Special Interest (AESIs) at day Day 180, censored by last telephone visit or death, whichever is later. |
Day 180 (6 months)
|
|
Number of participants by category-specific MDRO Colonization and survival status
Tidsramme: Day 28
|
Participants will be classified into one of three ordinal categories: (1) survival without colonization of the category-specific multidrug-resistant organism (MDRO), (2) survival with colonization of the category-specific MDRO, or (3) deceased. Category-specific MDRO colonization is defined as a stool culture at Day 28 positive for the category-specific MDRO being evaluated (e.g., ESBL, CRE, MDRP, or VRE). |
Day 28
|
Samarbeidspartnere og etterforskere
Sponsor
Samarbeidspartnere
Etterforskere
- Hovedetterforsker: Michael Woodworth, MD, Emory University
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Faktiske)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- STUDY00007230
- U54CK000601 (U.S. NIH-stipend/kontrakt)
- 2024P008055 (Annen identifikator: Emory IRB)
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
IPD-planbeskrivelse
Deidentified participant solicited adverse event and serious adverse event data will be shared.
Isolate genomic data and participant metagenomic data will be shared in public repositories (NCBI) at time of publication
IPD-delingstidsramme
Data will become available at time of publication.
Tilgangskriterier for IPD-deling
Sequence data access will not be restricted. Additional participant-level data will be shared by review of PI of proposing investigators and appropriate ethical approval (e.g. IRB) if any.
IPD-deling Støtteinformasjonstype
- STUDY_PROTOCOL
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .